VivoSim Labs, INC. (VIVS) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
VIVS currently has 2.6M outstanding shares. with significant dilution risk as 4.12M authorized shares could dilute existing holders by 158.3%. The company has significantly diluted shareholders by 99.12% over the past 2 years, indicating aggressive capital raising. Recent corporate actions include 1 stock split (positive for accessibility) and 1 reverse split (concerning signal).
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Apr 03, 2026 |
8-K filing: VivoSim Labs, Inc. priced a public offering of up to 3,508,772 shares of common stock or pre-funded warrants, together with accompanying common warrants; the initial tranche closed on April 1, 2026, with the issuance and sale of 286,557 shares of common stock and 2,345,022 pre-funded warrants. |
2.6M | 4.1M |
| Mar 31, 2026 |
S-1/A filing: This is a best efforts public offering of up to $4,000,000 of shares of common stock or pre-funded warrants in lieu thereof, together with accompanying common warrants to purchase shares of common stock. |
2.6M | 4.1M |
| Mar 27, 2026 |
S-1 filing: The filing is for a best efforts public offering of up to $4,000,000 of shares of common stock or pre-funded warrants, together with common warrants to purchase up to $15,000,000 of common stock. |
2.6M | 6.5M |
| Nov 06, 2025 |
10-Q filing | 2.6M shares outstanding |
2.6M | 450K |
| Aug 12, 2025 |
10-Q filing | 2.5M shares outstanding |
2.5M | 560K |
| Jun 05, 2025 |
10-K filing | 2.6M shares outstanding |
2.6M | 460K |
| Mar 20, 2025 |
Stock Split
8-K filing: Stock split 1-for-12 | Outstanding: 18,056,561 → 1,504,713 |
1.5M | 1.6M |
| Feb 19, 2025 |
10-Q filing | 18.1M shares outstanding |
18M | 19M |
| Nov 08, 2024 |
10-Q filing | 15.4M shares outstanding |
15M | 21M |
| Oct 25, 2024 |
S-1 filing: The company is offering shares of common stock, pre-funded warrants, and common warrants, with Roth Capital Partners, LLC acting as the lead placement agent. |
15M | 22M |
| Aug 05, 2024 |
10-Q filing | 14.7M shares outstanding |
15M | 22M |
| May 31, 2024 |
10-K filing | 14.4M shares outstanding |
14M | 22M |
| May 13, 2024 |
8-K filing: Organovo Holdings, Inc. priced a public offering of 1,562,500 shares of common stock and accompanying warrants, and pre-funded warrants to purchase 5,000,000 shares of common stock and accompanying warrants, at combined prices of $0.80 and $0.799 respectively, closing on May 13, 2024, with net proceeds of approximately $4.7 million. |
11M | 25M |
| Apr 30, 2024 |
S-1/A filing: The company is offering up to 10,000,000 shares of common stock together with common warrants to purchase up to 10,000,000 shares of common stock, as well as pre-funded warrants to certain purchasers. |
11M | 25M |
| Apr 23, 2024 |
8-K filing: Between February 1, 2024 and April 19, 2024, Organovo Holdings, Inc. issued 1,349,778 shares of Common Stock pursuant to an ATM Offering for total gross proceeds of approximately $1.8 million, resulting in 11,391,102 shares of Common Stock issued and outstanding as of April 19, 2024. ($1.8M proceeds) |
11M | 0 |
| Apr 12, 2024 |
S-1 filing: The company is offering common stock and pre-funded warrants to purchase common stock. The public offering price will be determined between the company and investors based on market conditions. |
9.1M | 0 |
| Feb 08, 2024 |
10-Q filing | 9.1M shares outstanding |
9.1M | 0 |
| Jan 26, 2024 |
S-3 filing: The filing is an S-3 registration statement for a shelf offering of up to $150,000,000 in the aggregate of common stock, preferred stock, debt securities, warrants, units, or rights. |
9.8M | 0 |
| Dec 28, 2023 |
8-K filing: Organovo Holdings, Inc. issued 65,789 shares of common stock to a consultant as compensation and issued 901,621 shares of common stock pursuant to an ATM Offering for total gross proceeds of approximately $1.2 million. The company has 9,805,755 shares of common stock issued and outstanding. ($1.2M proceeds) |
9.8M | 0 |
| Nov 09, 2023 |
10-Q filing | 8.7M shares outstanding |
8.7M | 0 |
| Aug 10, 2023 |
10-Q filing | 8.7M shares outstanding |
8.7M | 0 |
| Jul 14, 2023 |
10-K filing | 8.7M shares outstanding |
8.7M | 0 |
| Feb 09, 2023 |
10-Q filing | 8.7M shares outstanding |
8.7M | 0 |
| Nov 10, 2022 |
10-Q filing | 8.7M shares outstanding |
8.7M | 0 |
| Aug 11, 2022 |
10-Q filing | 8.7M shares outstanding |
8.7M | 0 |
| Jun 10, 2022 |
10-K filing | 8.7M shares outstanding |
8.7M | 0 |
| Feb 14, 2022 |
10-Q filing | 8.7M shares outstanding |
8.7M | 0 |
| Nov 08, 2021 |
10-Q filing | 8.7M shares outstanding |
8.7M | 0 |
| Aug 06, 2021 |
10-Q filing | 8.7M shares outstanding |
8.7M | 0 |
| Jun 15, 2021 |
10-K filing | 8.7M shares outstanding |
8.7M | 0 |
| Feb 08, 2021 |
10-Q filing | 7.1M shares outstanding |
7.1M | 0 |
| Jan 19, 2021 |
S-3 filing: The company files an S-3 to offer and sell up to $150,000,000 in the aggregate of common stock, preferred stock, and debt securities. They also have an at-the-market offering (ATM) for common stock through H.C. Wainwright& Co., LLC and JonesTrading Institutional Services LLC. |
6.7M | 0 |
| Nov 05, 2020 |
10-Q filing | 6.7M shares outstanding |
6.7M | 0 |
| Aug 18, 2020 |
Stock Split
8-K filing: Stock split 1-for-20 | Outstanding: 130,618,203 → 6,530,910 |
6.5M | 0 |
| Aug 10, 2020 |
10-Q filing | 130.6M shares outstanding |
130M | 0 |
| May 28, 2020 |
10-K filing | 130.6M shares outstanding |
130M | 0 |
| Feb 10, 2020 |
10-Q filing | 130.5M shares outstanding |
130M | 0 |